Sort by

Send to

Choose Destination

Links from PubMed

Items: 9


Early Impact of Fontan Operation on Enteric Protein Loss.

Patel JK, Loomes KM, Goldberg DJ, Mercer-Rosa L, Dodds K, Rychik J.

Ann Thorac Surg. 2016 Mar;101(3):1025-30. doi: 10.1016/j.athoracsur.2015.09.036. Epub 2015 Dec 1.


Fontan-associated protein-losing enteropathy and plastic bronchitis.

Schumacher KR, Stringer KA, Donohue JE, Yu S, Shaver A, Caruthers RL, Zikmund-Fisher BJ, Fifer C, Goldberg C, Russell MW.

J Pediatr. 2015 Apr;166(4):970-7. doi: 10.1016/j.jpeds.2014.12.068. Epub 2015 Feb 4.


Contractility-afterload mismatch in patients with protein-losing enteropathy after the Fontan operation.

Ozawa H, Ueno T, Iwai S, Kawata H, Nishigaki K, Kishimoto H, Sawa Y.

Pediatr Cardiol. 2014 Oct;35(7):1225-31. doi: 10.1007/s00246-014-0920-8. Epub 2014 May 15.


The effect of bosentan on exercise capacity in Fontan patients; rationale and design for the TEMPO study.

Hebert A, Jensen AS, Idorn L, Sørensen KE, Søndergaard L.

BMC Cardiovasc Disord. 2013 May 11;13:36. doi: 10.1186/1471-2261-13-36.


Orthotopic heart transplantation in patients with univentricular physiology.

Michielon G, Carotti A, Pongiglione G, Cogo P, Parisi F.

Curr Cardiol Rev. 2011 May;7(2):85-91. doi: 10.2174/157340311797484259. Review.


Clinical practice. Protein-losing enteropathy in children.

Braamskamp MJ, Dolman KM, Tabbers MM.

Eur J Pediatr. 2010 Oct;169(10):1179-85. doi: 10.1007/s00431-010-1235-2. Epub 2010 Jun 23. Review.


The Fontan pathway: What's down the road?

Khambadkone S.

Ann Pediatr Cardiol. 2008 Jul;1(2):83-92. doi: 10.4103/0974-2069.43872.


Report of the National Heart, Lung, and Blood Institute's Working Group on obesity and other cardiovascular risk factors in congenital heart disease.

Pemberton VL, McCrindle BW, Barkin S, Daniels SR, Barlow SE, Binns HJ, Cohen MS, Economos C, Faith MS, Gidding SS, Goldberg CS, Kavey RE, Longmuir P, Rocchini AP, Van Horn L, Kaltman JR.

Circulation. 2010 Mar 9;121(9):1153-9. doi: 10.1161/CIRCULATIONAHA.109.921544. Review. No abstract available.


Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function.

Bode L, Salvestrini C, Park PW, Li JP, Esko JD, Yamaguchi Y, Murch S, Freeze HH.

J Clin Invest. 2008 Jan;118(1):229-38.

Items per page

Supplemental Content

Support Center